Prelude Therapeutics Stock
Prelude Therapeutics Incorporated
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Krishna Vaddi
- Employees
- 79
- Market cap
- $189 M
- IPO
- 25/09/2020
Prelude Therapeutics, Inc. is a clinical-stage precision oncology company focused on identifying and developing innovative, targeted cancer treatments for patient populations with unmet medical needs. Its pipeline includes PRT543, currently undergoing Phase 1 clinical evaluation for certain solid tumors and myeloid…
Prelude Therapeutics stock: price history
1D
-1.8%
1W
-16.2%
1M
-27.1%
6M
-26.6%
YTD
+12.4%
1Y
+148.9%
2Y
+68.0%
5Y
-80.0%
10Y
–
Next earnings date
Next earnings date
11/11/2026 (in 25 days)
Volatility around earnings
~2% stronger price swings than usual
Pattern chart
Pattern detected by the Market Jury detector vdouble-bottom-top-v1.0 on 14/10/26. Not a buy or sell signal.Beta
What does this mean?
Double top
BearishThe price failed at a similar high twice, with a pullback in between. This M-shaped pattern is a classic reversal signal from an uptrend into a downtrend.
Chart patterns are a purely technical signal derived from price action. At Market Jury they do not feed into the agents' buy or sell decisions, they are supplementary information only.
Prelude Therapeutics stock scores
- Valuation
Visible after free registration
- Trend
Visible after free registration
- Quality
Visible after free registration
- Dividend
Visible after free registration
- Growth
Visible after free registration
- Insider
Visible after free registration
- Earnings
Visible after free registration
- Revisions
Visible after free registration
- Sentiment
Visible after free registration
- Short Pressure
Visible after free registration
Register for free
Unlock all 11 scores
- 5 credits free on registration
- Access to virtual portfolios and watchlist
- No credit card, no payment details needed
- No subscription, no minimum term
- Our own servers in Germany, no US cloud
Deterministically calculated from financial metrics, not investment advice. Updated nightly, last on 17/10/2026.
Business model & megatrends
Average business model without a clear megatrend link or with mixed signals.
Prelude Therapeutics is a clinical-stage biotechnology company specializing in precision oncology. The business model focuses on identifying and developing innovative, targeted cancer therapies for patient populations with unmet medical needs. The current pipeline comprises multiple drug candidates at various stages of development, with PRT543 and PRT811 already being investigated in Phase 1 studies for the treatment of solid tumors as well as hematologic malignancies. The company is also working on highly selective inhibitors to combat specific cancers such as glioblastoma multiforme or other genomically selected carcinomas.
- Revenue model
- Transactional
- Recurring revenue
- None
- Pricing power
- Weak
- Moat
- Narrow
- Moat type
- Regulatory
- Capital intensity
- High
- Customer concentration
- Unknown
Ask the agents about Prelude Therapeutics
Analyst assessment of Prelude Therapeutics
PRICE TARGET LOW
US$8.00
CONSENSUS
US$8.00
MEDIAN
US$8.00
PRICE TARGET HIGH
US$8.00
0
STRONG BUY
5
BUY
1
HOLD
2
SELL
0
STRONG SELL
8
TOTAL · Buy
As of: 29/07/2026
Prelude Therapeutics stock metrics
P/E
-4.13
P/B
2.4
EV/EBITDA
-3.06
RETURN ON EQUITY
-10.4%
NET MARGIN
-244.1%
DEBT/EQUITY
0.13
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
56.0%
FLOAT SHARES
44,729,442
AVG. DAILY VOLUME (30D)
481,831
Insider transactions (SEC)
RA CAPITAL MANAGEMENT, L.P.
Attention
1 mention today in US forums, about the same as yesterdayPrice since yesterday: -1.8%
Forums (Reddit)
Institutional holders
Comparable stocks
Frequently asked questions about Prelude Therapeutics stock
What does Prelude Therapeutics do?
Prelude Therapeutics Incorporated is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Krishna Vaddi, the company employs around 79 people.
The IPO was on 25/09/2020; the stock trades on NASDAQ under the ticker PRLD.
What do analysts say about Prelude Therapeutics stock?
8 analysts rate the stock, the consensus is Buy (as of 29/07/2026).
The average price target is US$8.00, ranging from US$8.00 to US$8.00, with a median of US$8.00.
This is an external assessment, not a statement by Market Jury.
When does Prelude Therapeutics report next?
The next earnings date is 11/11/2026.
Around past earnings, price swings were roughly 2% stronger than usual.
Does Prelude Therapeutics pay a dividend?
No, Prelude Therapeutics currently does not pay a dividend.
Which stocks are comparable to Prelude Therapeutics?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Prelude Therapeutics stock analyzed?
Clicking "Analyze stock" lets five strategies assess Prelude Therapeutics against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.